Case Report

A Rare Case of Endophthalmitis with *Rhizobium radiobacter*, Soon after a Resolved Keratitis: Case Report

Andrei Theodor Balasoiu 1, Ovidiu Mircea Zlatian 2,*, Alice Elena Ghenea 2,*, Livia Davidescu 3, Alina Lungu 4, Andreea Loredana Golli 5, Anca-Loredana Udris tüiu 6 and Maria Balasoiu 2

1 Department of Ophthalmology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; andrei_theo@yahoo.com
2 Department of Bacteriology-Virology-Parasitology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; balasoiu.maria@yahoo.com
3 Department of Ophthalmology, County Clinical Emergency Hospital of Craiova, 200642 Craiova, Romania; liviadavidescu@yahoo.com
4 Department of Infectious diseases, County Clinical Emergency Hospital of Craiova, 200642 Craiova, Romania; marinaalina@gmail.com
5 Department of Epidemiology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania; andreea_golli@yahoo.com
6 Faculty of Automation, Computers and Electronics, University of Craiova, 200776 Craiova, Romania; anca.udristoiu@edu.ucv.ro
* Correspondence: ovidiu.zlatian@gmail.com (O.M.Z.); gaman_alice@yahoo.com (A.E.G.)

Abstract: Background: *Rhizobium (Agrobacterium)* species are plant aerobic bacteria, which in some cases can produce endophthalmitis in humans after corneal trauma. Case presentation: A 42-year-old female patient presented in the Emergency Department of the Emergency County Hospital of Craiova, Romania, reporting pain, epiphora, and blurry vision in her right eye for about five days. This initial infectious keratitis episode was successfully resolved, but after 20 days she presented again after trauma with a leaf with corneal abscess. In the conjunctival secretion, *R. radiobacter* was identified. Despite antibiotherapy, the patient’s state did not improve, and ultimately the eye was eviscerated. Methods: A search was performed in the ProQuest, PubMed, and ScienceDirect databases for the terms Agrobacterium, Rhizobium, radiobacter, and eye. We eliminated non-human studies, editorials and commentaries, and non-relevant content, and excluded the duplicates. Results: In total, 138 studies were initially obtained, and then we selected 26 studies for retrieval. After the selection process, we ended up including 17 studies in our analysis. Most studies reported *R. radiobacter* endophthalmitis after ocular surgical procedures or outdoor activities that involve exposure to soil. Conclusion: *R. radiobacter* is a rare cause of endophthalmitis after eye trauma that generally responds well to usual antibiotherapy, but occasionally can evolve to severe, leading to the loss of the eye.

Keywords: *Rhizobium radiobacter*; endophthalmitis; cataract surgery; corneal trauma

1. Introduction

Endophthalmitis is a leading cause of eye loss worldwide, despite the prophylactic antibiotherapy used for eye trauma, whether accidental or surgical [1–4]. Table 1 summarizes the main infectious agents involved in endophthalmitis, which is caused by different mechanisms, including trauma, eye surgery, contact lenses, eye injections or other related procedures, or hematological inoculation.
Table 1. Etiology of endophthalmitis by type.

| Endophthalmitis Type                  | Etiology                                                                                                                                                                                                                                                                                                                                 | Recommended Intravitreal Treatment      | Recommended Systemic Antibiotics                  |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|-----------------------------------------------|
| After cataract surgery              | Staphylococcus epidermidis, Staphylococcus warneri, Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus aureus, Propionibacterium acnes, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus intermedius, Abiotrophia defectiva, Bacillus cereus, Pseudomonas aeruginosa, Pseudomonas stutzeri, Klebsiella pneumoniae, Haemophilus influenzae, Acinetobacter baumannii, Agrobacterium tumefaciens, Citrobacter freundii, Rhizobium radiobacter, Escherichia coli, Enterococcus faecalis, Stenotrophomonas maltophilia, Mycobacterium chelonae, Propionibacterium acnes (in chronic cases), fungi (Candida albicans, Candida parapsilosis, Acremonium strictum, Aspergillus fumigatus, Paecilomyces variotii, Fusarium proliferatum) [5–12] | Vancomycin, ceftazidime Rarely used   | Vancomycin, ceftazidime Rarely used (in severe cases) |
| After intravitreal injections       | Staphylococcus aureus, Streptococcus viridans, Streptococcus mitis, Streptococcus viridans, Enterococcus faecalis [3,13]                                                                                                                                                                                                                  | Vancomycin, ceftazidime                 | Quinolones (moxifloxacin)                     |
| After eye traumatism                | Staphylococcus aureus, S. epidermidis, S. capitis, Staphylococcus warneri, S. pasteuri, S. auricularis, S. piscifermentans, S. lugdunensis, Streptococcus mutans, S. salivarium, S. mutans, S. oralis, S. sanguinis, S. vestibularis, S. thermophiles, Enterococcus faecalis, Rhizobium radiobacter, Bacillus cereus, Escherichia coli, Candida parapsilosis, Candida albicans, Candida glabrata, Candida famata, Aspergillus flavus, Aspergillus fumigatus, Propionibacterium acnes [10,14,15] | Vancomycin, ceftazidime, amphotericin (if suspicion of fungal infection) | Vancomycin, ceftazidime, ciprofloxacin         |
| After Baerveldt tube exposure       | Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus mitis, Corynebacterium spp., Pseudomonas aeruginosa, Aspergillus flavus, Aspergillus fumigatus [16]                                                                                                                                                                        | Vancomycin, ceftazidime                 | Rarely used                                  |
| (in glaucoma treatment)             |                                                                                                                                                                                                                                                                                                                                       |                                        |                                               |
| After long-term wear of contact lenses | Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus epidermidis, Staphylococcus aureus, Streptococcus mitis, Streptococcus salivarium, Streptococcus mutans, Streptococcus pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Propionibacterium acnes [17] | Aminoglycosides, fluoroquinolones, 3rd-generation cephalosporins, vancomycin | Rarely used                                  |
| Endogenous endophthalmitis         | Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Kingella kingae, Pseudomonas aeruginosa, (Candida albicans, Candida parapsilosis, Candida glabrata, Aspergillus flavus, Aspergillus fumigatus) [18–20] | Vancomycin, ceftazidime (or amikacin) | Antibiotics according to etiology            |

A rare cause of endophthalmitis is infection with Rhizobium (Agrobacterium) radiobacter, which is a plant aerobic bacterium belonging to the Gram-negative bacilli, which are common in the environment—especially in soil [21]—and cause plant diseases such as gall tumors and hairy root disease. Several cases of Rhizobium radiobacter endophthalmitis have been reported, usually after cataract surgery, but have only rarely been reported to produce human infections, most often in immunocompromised patients [22–25]. The main risk factors are non-adherence to aseptic techniques [26,27], paracentesis of the anterior chamber, and eyelid manipulation [2,28].

Here, we describe a case of bacterial keratitis with severe evolution.

2. Case Report

A 42-year-old female patient presented in the Emergency Department of the Emergency County Hospital of Craiova, Romania, on 4 April 2022, reporting pain, epiphora, and blurry vision in her right eye for about five days. Anamnesis revealed a history of chemically treated soil contact with her right eye about seven days before the presentation, as she lives in the countryside and works in agriculture. The patient had not been immunocompromised or treated with steroids. Uncorrected visual acuity was 0.25 in her right eye and 1 in her left eye; the best-corrected visual acuity (BCVA) in her right eye was 0.25 (normal visual acuity is 1). Intraocular pressure (IOP) was 17 mmHg in her right eye.
and 15 mmHg in her left eye (the normal range is between 10 and 21 mmHg). Slit-lamp examination in the right eye revealed conjunctival hyperemia, a 4 mm white–yellow central corneal ulceration with infiltrated margins that retained the methylene blue stain, Descemet folds at the lesion and endothelial edema, a normal-depth anterior chamber, less than five cells in the aqueous, miotic, and reflexive pupil (Figure 1). Due to corneal haze, fundus examination was difficult to perform in the right eye, but it was normal in the left eye. Corneal sensitivity was tested in the right eye, and the result was hyperesthesia. A clinical diagnosis of infectious keratitis of the left eye was established. A SARS-CoV-2 rapid antigen test was performed, and as it was negative the patient was admitted to hospital in the Ophthalmology Clinic.

![Figure 1. Slit-lamp examination of the right eye showing conjunctival hyperemia, a 4 mm white–yellow central corneal ulceration with infiltrated margins that retains the stain, Descemet folds at the lesion, and endothelial edema (methylene blue staining).](image)

Conjunctival secretion and corneal scraping samples were collected and sent to the hospital’s laboratory for microbiology diagnosis and antibiogram; standard blood tests were also performed. Intravenous empirical broad-spectrum antibiotherapy was introduced immediately after sampling (third-generation cephalosporin/beta-lactamase inhibitor—cefoperazone/sulbactam), doubled by local antibiotherapy (topical moxifloxacin). Lubricants, mydriatics, topical NSAIDs, and eye patching were also prescribed.

Microbiology results were negative for bacteria and fungi; the rest of the tests were also normal. Fortunately, the evolution was favorable: the ulceration’s size started to decrease daily, the Descemet folds became thinner, and visual acuity was also improving, so on 10 April 2022, the patient was discharged from hospital. Clinical examination of the right eye that day revealed that the uncorrected visual acuity was 0.9, IOP was 16 mmHg, the slit-lamp examination showed minimal conjunctival hyperemia, paracentral corneal 3 mm leucoma, and a quiet anterior chamber, and the fundus was also normal. The recommendation was topical treatment with lubricants, moxifloxacin, and NSAIDs, and ambulatory appointment after one week.

The patient presented ambulatory, one week after hospital discharge, in the Ophthalmology Clinic, where the slit-lamp examination revealed a quiet right eye, no conjunctival hyperemia, paracentral corneal 3 mm leucoma, normal aspect of the fundus, and 0.9 visual acuity. Topical antibiotics and NSAIDs were interrupted after this examination, but the eye lubricants were kept and the patient returned to work.

On 29 April 2022, the patient presented again in the Emergency Department of the Emergency County Hospital of Craiova, Romania, reporting severe pain, photophobia, epiphora, and a severe decrease in visual acuity in her right eye. The symptoms started four to five days before the presentation; she linked the debut with eye trauma caused by plant leaves. Visual acuity in the right eye was counting fingers at two meters, IOP
was 18 mmHg, and the slit-lamp examination revealed a 6 mm white corneal abscess with perilesional infiltration, thick Descemet folds, Tyndall ++, and myotic pupil. The clinical diagnosis was corneal abscess with exogenous uveitis of the right eye. A SARS-CoV-2 rapid antigen test was performed, and as it was negative the patient was admitted to hospital in the Ophthalmology Clinic.

Conjunctival secretions and corneal scrapings were again collected and sent to the hospital’s laboratory for microbiology diagnosis and antibiogram; standard blood tests were also performed (10.6 × 10³/µL leukocytosis and 87.3%/9.2 × 10³/µL neutrophilia). Intravenous empirical double antibiotherapy was introduced immediately after sampling (third-generation cephalosporin/beta-lactamase inhibitor—cefoperazone/sulbactam and gentamycin), doubled by local antibiotherapy (topical levofloxacin). Lubricants, mydriatics, topical NSAIDs, and eye patching were also prescribed. The patient presented dizziness, nausea, and a body temperature raised to 37.5 °C; thus, she was booked for examination in the Internal Medicine Clinic. The general examination did not stress any pathological findings, and blood pressure was 100/60 mmHg. Recommendations were as follows: RT PCR SARS-CoV-2 (which was negative), hemoculture if the temperature rises above 38 °C (did not happen), hydration (according to blood pressure), and NSAIDs in case of fever.

The evolution was unfavorable as the visual acuity decreased to counting fingers at one meter, the corneal abscess remained the same size, a 2 mm hypopyon appeared, and the subjective pain increased (30 April). An infectious disease specialist was asked to see the patient, and the recommendations were as follows: further serological investigations for HIV, cytomegalovirus, and hepatitis viruses B and C, which were negative. It was also recommended to stop cefoperazone/sulbactam + gentamicin therapy and change to a teicoplanin + azithromycin regimen. Despite antibiotic changes, the patient’s state did not improve: visual acuity in the right eye was limited to hand movement, the whole cornea was infiltrated, the abscess was 6–7 mm, and the hypopyon was 3–4 mm (1 May) (Figure 2).

![Figure 2](image)

**Figure 2.** Slit-lamp examination of the right eye highlighting severe conjunctival hyperemia, infiltrated cornea, 6–7 mm central corneal abscess, and hypopyon.

The microbiology results then came in. Bacteriologically, the samples were inoculated under aerobic, anaerobic, and microaerophilic conditions in Columbia blood agar, chocolate agar supplemented with PVX, and MacConkey culture medium for 24 h at 37 °C in aerobiose (48 h in anaerobiose and microaerophily). We observed in both samples on blood agar in large (2–4 mm), convex, non-pigmented, light beige, non-hemolytic, raised aerobiotic colonies, with a dry central portion and wet at the edges (Figure 3).
Figure 2. Slit-lamp examination of the right eye highlighting severe conjunctival hyperemia, infiltrated cornea, 6–7 mm central corneal abscess, and hypopyon.

The microbiology results then came in. Bacteriologically, the samples were inoculated under aerobic, anaerobic, and microaerophilic conditions in Columbia blood agar, chocolate agar supplemented with PVX, and MacConkey culture medium for 24 h at 37°C in aerobiosis (48 h in anaerobiosis and microaerophily). We observed in both samples on blood agar in large (2–4 mm), convex, non-pigmented, light beige, non-hemolytic, raised aerobic colonies, with a dry central portion and wet at the edges (Figure 3).

Biochemically, the strain was glucose-non-fermenting, oxidase-positive, mobile, indole-negative, and urease-positive. The biochemical identification on a VITEK2 automated system (Biomerieux) with a GN card identified R. radiobacter with 99% probability after 3.8 h of analysis (Figure 4).

Figure 3. Radiobacter colonies on Columbia blood agar.

Biochemically, the strain was glucose-non-fermenting, oxidase-positive, mobile, indole-negative, and urease-positive. The biochemical identification on a VITEK2 automated system (Biomerieux) with a GN card identified R. radiobacter with 99% probability after 3.8 h of analysis (Figure 4).

In the microscopic exam we observed long and thin unsporulated Gram-negative rods with a tendency of adhesion between them (Figure 5).

Antibiotic susceptibility testing on the VITEK2 Compact system using the card AST-N223/AST-NX05 showed susceptibility to ticarcillin and ticarcillin–clavulanate (MIC ≤ 8), piperacillin and piperacillin–tazobactam (MIC ≤ 4), cefepime (MIC ≤ 1), imipenem, and meropenem (MIC ≤ 0.25). Aminoglycosides were also susceptible (amikacin MIC ≤ 2, gentamycin MIC ≤ 1, tobramycin ≤ 1), as were the quinolones (ciprofloxacin/ofloxacin MIC ≤ 0.25 and levofloxacin MIC ≤ 0.12). The strain was resistant to colistin (MIC ≥ 16). The MIC for tigecycline was ≤0.5, which the system interpreted as resistant.
In the microscopic exam we observed long and thin unsporulated Gram-negative rods with a tendency of adhesion between them (Figure 5).

On 2 May 2022, the patient requested transfer to the Emergency Eye Diseases Hospital in Bucharest, Romania, and it was granted. The right eye status was as follows: visual acuity was light perception, severe conjunctival hyperemia, infiltrated cornea, 6–7 mm corneal abscess, 4 mm hypopyon, and fundus examination was not possible due to corneal opacity. The clinical and microbiological diagnosis was severe bacterial keratitis (corneal abscess with \( R. \text{radiobacter} \)) and exogenous endophthalmitis.

Unfortunately for this patient, the evolution was unfavorable, and within days after she was transferred to Bucharest the eye was eviscerated to prevent orbital, sinus, and cerebral infection complications.

3. Systematic Review

We searched ProQuest, PubMed, and ScienceDirect for the terms Agrobacterium, Rhizobium, radiobacter, and eye (the exact search string was “(Agrobacterium OR Rhizobium) AND radiobacter and eye”). The eligibility criteria included human studies of infections of the eye with \( R. \text{radiobacter} \), and all article types except for comments, editorials, etc. The database search yielded 138 studies: 96 from the ProQuest database, 8 from PubMed, and 34 from ScienceDirect; 110 studies were not retrieved as they were non-human studies. We excluded two more studies as they were editorials or comments. Therefore, we selected 26 studies for retrieval: 7 studies from the PubMed database, 10 from ProQuest, and 9 from ScienceDirect; 5 studies were duplicates. We excluded 4 more studies from the analysis after reading the abstracts: two studies identified \( R. \text{radiobacter} \) in solutions used for the storage of contact lenses \([29,30]\); one study referred to sepsis with \( R. \text{radiobacter} \) originating from a central venous catheter \([31]\); and one study identified this pathogen in surgical equipment used in ophthalmology (vacuum control manifold) \([32]\) (Figure 6).

Rohowetz et al. \([33]\) reported endophthalmitis with \( R. \text{radiobacter} \) in a 79–year-old male patient with type II diabetes mellitus and diabetic retinopathy, who received treatment with intravitreal aflibercept. The patient was treated empirically with intravitreal injections of ceftazidime and vancomycin. After the laboratory results came in, the patient’s therapy was changed to oral azithromycin and levofloxacin. The infection was resolved at 1-month follow-up.
Therefore, we included 17 studies in the systematic review (Table 2).

The same author, one year later, reported a case of endophthalmitis in an 85-year-old male associated with insertion of an inferonasal Baerveldt tube [34]. *R. radiobacter* was identified in aqueous humor culture, and was resistant to ceftazolin, ceftazidime, amikacin, tobramycin, and trimethoprim–sulfamethoxazole. Because the explantation of the drainage implant was not efficient, pars plana vitrectomy was performed with removal of the intraocular lens, associated with silicone oil infusions and intravitreal antibiotics. The patient’s visual acuity improved after 2 weeks, but then it was lost to follow-up.
Table 2. The studies included in this review.

| Authors                  | Journal                          | Title                                                                 | Article Type | No. of Samples/Patients | Mean Age (Years) | Pre-Existent Eye Conditions | Eye Trauma        | Antibiotic Susceptibility Results                                                                 | Drug Therapy                                                                 | Outcome                        |
|--------------------------|----------------------------------|----------------------------------------------------------------------|--------------|-------------------------|------------------|-----------------------------|-------------------|------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|--------------------------------|
| Robowetz et al.          | Case Reports in Ophthalmology    | Endophthalmitis: Caused by Agrobacterium radiobacter Following Intravitreal Aflibercept for Diabetic Retinopathy | Case report  | 1                       | 79               | Diabetic retinopathy        | Intravitreal aflibercept | -                                                                              | Intravitreal vancomycin and azithromycin; oral gentamicin and levofloxacin | Infection resolved               |
| Robowetz et al.          | Case Reports in Ophthalmology    | Agrobacterium radiobacter: Endophthalmitis Associated with Baerveldt Tube Exposure | Case report  | 1                       | 85               | Angle-closure glaucoma      | Baerveldt tube insertion | Resistance to cefazolin, ceftazidime, amikacin, tobramycin, and trimethoprim-sulfamethoxazole | Injection of intravitreal vancomycin (1 mg) and ceftazidime (2.25 mg). Drops of 0.5% moxifloxacin every 2 h. Injection of 0.2 mg of intravitreal gentamicin | Visual acuity improvement after 2 weeks and then lost to follow-up |
| Barker et al.            | Cornea                           | Rhizobium radiobacter: A Recently Recognized Cause of Bacterial Keratitis | Case series  | 4                       |                  | None identified             | Cement-splash injury    | Susceptibility to ciprofloxacin and minocycline                                      | Moxifloxacin drops. Oral ketoconazole. Ciprofloxacin drops hourly and oral ciprofloxacin (250 mg) twice daily | Infection resolved               |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
|                          |                                  |                                                                      |              |                         |                  |                             |                   |                                                                                                                                          |                                                                                |
| Authors | Journal | Title | Article Type | No. of Samples/ Patients | Mean Age (Years) | Pre-Existing Eye Conditions | Eye Trauma | Antibiotic Susceptibility Results | Drug Therapy | Outcome |
|---------|---------|-------|--------------|--------------------------|-----------------|---------------------------|------------|-----------------------------------|--------------|---------|
| Fenner et al. (2019) | American Journal of Ophthalmology Case Reports | Case of Isolated *Rhizobium radiobacter* Contact-Lens-Related Infectious Keratitis: A Plant Microbe Now Emerging as a Human Pathogen | Case report | 1 | 26 | Contact lens wearer | - | Susceptibility to cefepime, ciprofloxacin, and gentamicin | Hourly cefazolin (50 mg/mL) and gentamicin (14 mg/mL). Hourly 0.02% chlorhexidine. Hourly 1.5% levofloxacin, hourly cefazolin, and two-hourly chlorhexidine to both eyes during waking hours, and 0.3% ciprofloxacin ointment overnight. Levofloxacin 1.5% monotherapy for both eyes at four weeks | Favorable evolution with central anterior-to-mid-stromal scar |
| Al-Abdullah et al. (2015) | Journal of Refractive Surgery | Endophthalmitis Caused by *Rhizobium radiobacter* After Posterior Chamber Phakic Intraocular Lens Implantation to Correct Myopia | Case report | 1 | 29 | Myopia | Posterior chamber phakic intraocular lens implantation | - | Intravitreal injections of vancomycin and ceftazidime | Infection resolved |
| Mishra et al. (2019) | The British Journal of Ophthalmology | Utility of Broad-Range 16S rRNA PCR Assay Versus Conventional Methods for Laboratory Diagnosis of Bacterial Endophthalmitis in a Tertiary Care Hospital | Research article | 8 out of 195 vitreous aspirates from endophthalmitis patients | - | - | Cataract surgery | Susceptible to all tested antibiotics (according to document M45 of CLSI 2010 [38]) | - | - |
| Shirodkar et al. (2015) | American Journal of Ophthalmology | Delayed- Versus Acute-Onset Endophthalmitis after Cataract Surgery | Research article | 1 out of 119 patients with endophthalmitis | - | - | Cataract surgery | - | - |
| Hsu et al. (2013) | American Journal of Ophthalmology | Ocular Flora and their Antibiotic Resistance Patterns in the Midwest: A Prospective Study of Patients Undergoing Cataract Surgery | Research article | 1 out of 183 conjunctival cultures | - | - | Cataract surgery | Susceptible to cefazolin, ceftazidime, gentamicin, tobramycin, amikacin, ciprofloxacin, and levofloxacin | - | - |
### Table 2. Cont.

| Authors            | Journal                                      | Title                                                                 | Article Type       | No. of Samples/Patients | Mean Age (Years) | Pre-Existing Eye Conditions | Eye Trauma | Antibiotic Susceptibility Results | Drug Therapy | Outcome |
|--------------------|----------------------------------------------|----------------------------------------------------------------------|--------------------|-------------------------|------------------|-------------------------------|------------|----------------------------------|--------------|---------|
| Harbiyeli et al. (2021) [39] | International Ophthalmology                  | Clinical Aspects and Prognosis of Polymicrobial Keratitis Caused by Different Microbial Combinations: A Retrospective Comparative Case Study | Research article   | 1 out of 44 corneal scrapings | -                | Polymicrobial keratitis        | -          | Susceptible to ciprofloxacin and moxifloxacin | -            | -       |
| Haapala et al. (2005) [7] | Graef's Archive for Clinical and Experimental Ophthalmology | Endophthalmitis Following Cataract Surgery in Southwest Finland from 1987 to 2000 | Research article   | 1 out of 47 patients | -                | -                            | -          | -                                | -            | -       |
| Tellegen et al. (2009) [40] | Journal of Clinical Pathology                | Diagnosis of Conjunctivitis in Primary Care: Comparison of Two Different Culture Procedures | Research article   | 1 out of 88 patients | -                | Infectious conjunctivitis     | -          | -                                | -            | -       |
| Chiquet et al. (2016) [10] | The British Journal of Ophthalmology        | Occurrence and Risk Factors for Retinal Detachment after Pars Plana Vitrectomy in Acute Post-Cataract Bacterial Endophthalmitis | Research article   | 1 out of 123 vitreous aspirates | -                | -                            | -          | Post-cataract bacterial endophthalmitis treated with pars plana vitrectomy | -            | -       |
| Ambiya et al. (2016) [8] | Journal of Ophthalmic Inflammation and Infection | Comparison of Clinico-Microbiological Profile and Treatment Outcome of In-House and Referred Post-Cataract-Surgery Endophthalmitis in a Tertiary Care Center in South India | Research article   | 1 out of 100 patients | -                | -                            | Cataract surgery | Susceptible to amikacin, ceftazidime, gatifloxacin, moxifloxacin, ciprofloxacin, and ofloxacin. Resistant to chloramphenicol | Intraocular antibiotics (1 mg of vancomycin in 0.1 mL of normal saline; 2.25 mg of ceftazidime in 0.1 mL of normal saline). Intravitreal dexamethasone (0.4 mg in 0.1 mL). Topical 1% prednisolone acetate (every 4 h). Cyclopellia. Systemic ciprofloxacin (1500 mg/day in two divided doses) | -            | -       |
### Table 2. Cont.

| Authors                  | Journal                                | Title                                                                 | Article Type | No. of Samples/Patients | Mean Age (Years) | Pre-Existing Eye Conditions | Eye Trauma | Antibiotic Susceptibility Results                                                                 | Drug Therapy                                                                 | Outcome                                                                 |
|--------------------------|----------------------------------------|----------------------------------------------------------------------|--------------|-------------------------|-------------------|-----------------------------|------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Ness et al. (2011) [9]   | The Journal of Hospital Infection      | Postoperative Nosocomial Endophthalmitis: Is Perioperative Antibiotic Prophylaxis Advisable? A Single Centre’s Experience | Research article | 1 out of 16 patients with endophthalmitis | -                  | -                           | Cataract surgery | Susceptibility to gentamicin, ciprofloxacin, and ofloxacin                                                                 | -                                                                          | -                                                                        |
| Chiquet et al. (2009) [41] | Ophthalmology                          | Analysis of Diluted Vitreous Samples from Vitrectomy is Useful in Eyes with Severe Acute Postoperative Endophthalmitis | Research article | 1 out of 34 patients with endophthalmitis | -                  | Diabetes mellitus immunosuppression | Cataract surgery | -                                                                                           | -                                                                          | -                                                                        |
| Friling (2019) [11]      | The Journal of Hospital Infections     | Bacteriology and Cefuroxime Resistance in Endophthalmitis Following Cataract Surgery before and after the Introduction of Prophylactic Intracameral Cefuroxime: A Retrospective Single-Centre Study | Research article | 3 out of 95 patients with endophthalmitis | -                  | -                           | Cataract surgery | -                                                                                           | Intravitreal injection of 1 mg of ceftazidime; 2.27 mg of ceftazidime and 1 mg of vancomycin. Oral dose of prednisone (60 mg for five days) | -                                                                        |
| Namdari et al. (2003) [42] | Journal of Clinical Microbiology       | Rhizobium (Agrobacterium) radiobacter Identified as a Cause of Chronic Endophthalmitis Subsequent to Cataract Extraction | Case report   | 1                        | 62                 | Uncomplicated cataract extraction | -          | Susceptibility to ciprofloxacin resistance to ceftazidime and vancomycin | Intravitreal injection of amikacin (0.4 mg) and vancomycin (1 mg). Intravitreal administration of gentamicin (0.4 mg). Oral ciprofloxacin (500 mg twice daily for 10 days) | Infection resolved                                                      |
Barker et al. [35] reported a series of four cases with *R. radiobacter* in young patients: one after corneal traumatism and three in long-term contact lens wearers. The patients were treated with steroidal anti-inflammatory drugs and with antibiotic drops. All cases had a favorable evolution, with total sight recovery. Furthermore, Fenner et al. [36] reported keratitis in a young patient who was a contact lens wearer.

Another case of *R. radiobacter* infection was reported after phakic intraocular lens implantation in the posterior chamber of the eye in a young patient (29 years old) with myopia [37]. The endophthalmitis was resolved after intravitreal injections of vancomycin and ceftazidime.

One study identified one strain of *R. radiobacter* (1.14%) in 88 patients expressing symptoms consistent with conjunctivitis [40]. Another study included 44 patients with polymicrobial keratitis, from which *R. radiobacter* was isolated in one case (2.27%).

Nine studies were research articles, which included 912 patients who had undergone cataract surgery [4–11,41]. From those, in 18 cases (1.97%), *R. radiobacter* was isolated. In 7 of those 18 cases, *R. radiobacter* was associated with endophthalmitis, but in the remaining 11 cases it was considered an environmental contaminant. Moreover, Namdari et al. [42] in 2003 reported a case of chronic endophthalmitis after cataract extraction produced by *R. radiobacter*, which was resistant to vancomycin, amikacin, and ceftazidime—drugs often used in empirical therapy. Ultimately, the infection was resolved after changing the therapy to intravitreal injections of gentamycin and oral ciprofloxacin.

Therefore, endophthalmitis with *R. radiobacter* is rare, and is usually encountered after cataract surgery—mostly in old people and immunosuppressed patients, but also in young patients who wear contact lenses for extended periods of time.

### 4. Discussion

*Rhizobium* is a rare agent of endophthalmitis in patients who come into contact with plants [21]. Initially classified as *Agrobacterium*, after the introduction of 16s RNA genetic sequencing in the 1990s, many species were reclassified into the genus *Rhizobium*. The genus is divided into species based largely on pathogenic properties in plants: *R. radiobacter* (non-pathogenic), *R. tumefaciens* (the causative agent of crown gall tumors), *R. rhizogenes* (the causative agent of hairy root disease), and *R. vitis* (the causative agent of tumors and necrotic disease on grapevines). There are also less well-studied proposed species such as *R. rubi* isolated from cane galls on *Rubus* plant species.

The first *Rhizobium* strains were isolated from human infections in 1967 [43]. The first infection with *R. radiobacter* was reported in a case of endocarditis on a prosthetic valve [44]. In 1996, the first case of *Rhizobium radiobacter* endophthalmitis was reported after cataract surgery [42] and intravitreous injections [45]. Few cases have been reported since then [33]. In our clinic, this is the first confirmed case of *R. radiobacter* endophthalmitis.

The reported cases of ocular *R. radiobacter* infections occurred after traumatic medical procedures involving the eye, such as cataract surgery [42] or intravitreal injections [33]. Our patient, however, developed endophthalmitis after eye trauma caused by a plant leaf. In this case, our understanding is that the first episode was a local infection, which indeed resolved, but acted as a risk factor for infection with *R. radiobacter* after the eye trauma caused by the plant leaf. Indeed, as *Rhizobium* species are predominantly found in soil and plants, it is thought that cases of endophthalmitis after eye surgery are associated with outdoor activities and contamination of the eye with dust.

Although *R. radiobacter* infections are usually reported in immunocompromised hosts, our patient was immunocompetent; in this case, the eye trauma directly inoculated the eye with the pathogen at a much higher dose than that found in dust that contaminated the eye after medical procedures in other reported cases.

### 5. Conclusions

To summarize, *R. radiobacter* is a soil bacterium that rarely causes human infection. Nevertheless, patients with eye surgery or other procedures that provide a continuity
solution of the cornea, including endophthalmitis, can develop endophthalmitis following exposure to soil. It is therefore recommended that patients who undergo surgical procedures such as cataract surgery or intravitreal injections should avoid outdoor activities that involve exposure to soil and plants (yardwork, farming, etc.).

Author Contributions: Conceptualization, A.T.B., A.E.G., O.M.Z., and M.B.; methodology, A.T.B., A.-L.U., and A.E.G.; software, A.E.G., O.M.Z., A.-L.U., and A.T.B.; validation, A.T.B., A.E.G., M.B., and O.M.Z.; formal analysis, O.M.Z., L.D., A.L., A.L.G., and A.E.G.; resources, A.T.B., O.M.Z., and A.E.G.; data curation, L.D., A.T.B., M.B., and A.L.; writing—original draft preparation, A.T.B., A.E.G., O.M.Z., and M.B.; writing—review and editing, A.E.G., A.T.B., O.M.Z., L.D., A.-L.U., and M.B.; supervision, M.B., A.E.G., and A.T.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from the subject of this report. Written informed consent has been obtained from the patient to publish this paper.

Data Availability Statement: The data presented in this study are available upon request from the corresponding author.

Acknowledgments: The Article Processing Charges were funded by the University of Medicine and Pharmacy of Craiova, Romania.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Kowalski, R.P.; Nayyar, S.V.; Romanowski, E.G.; Shanks, R.M.Q.; Mammen, A.; Dhaliwal, D.K.; Jhanji, V. The Prevalence of Bacteria, Fungi, Viruses, and Acanthamoeba from 3004 Cases of Keratitis, Endophthalmitis, and Conjunctivitis. Eye Contact Lens 2020, 46, 265–268. [CrossRef] [PubMed]
2. Helbig, H.; Noske, W.; Kleineidam, M.; Kellner, U.; Foerster, M.H. Bacterial Endophthalmitis after Anterior Chamber Paracentesis. Br. J. Ophthalmol. 1995, 79, 866. [CrossRef] [PubMed]
3. Hoevenaars, N.E.D.; Gans, D.; Missotten, T.; van Rooij, J.; Lesaffre, E.; van Meurs, J.C. Suspected Bacterial Endophthalmitis Following Intravitreal Anti-VEGF Injection: Case Series and Literature Review. Ophthalmol. J. Int. D’ophtalmol. Int. J. Ophthalmol. Z. Augenheilkd. 2012, 228, 143–147. [CrossRef] [PubMed]
4. Mishra, D.; Satpathy, G.; Chawla, R.; Venkatesh, P.; Ahmed, N.H.; Panda, S.K. Utility of Broad-Range 16S RNA PCR Assay versus Conventional Methods for Laboratory Diagnosis of Bacterial Endophthalmitis in a Tertiary Care Hospital. Br. J. Ophthalmol. 2019, 103, 152–156. [CrossRef]
5. Hsu, H.Y.; Lind, J.T.; Tseng, L.; Miller, D. Ocular Flora and Their Antibiotic Resistance Patterns in the Midwest: A Prospective Study of Patients Undergoing Cataract Surgery. Am. J. Ophthalmol. 2013, 155, 36–44.e2. [CrossRef]
6. Shirodkar, A.R.; Pathengay, A.; Flynn, H.W.; Albini, T.A.; Berrocal, A.M.; Davis, J.L.; Lalwani, G.A.; Murray, T.G.; Smiddy, W.E.; Miller, D. Delayed- versus Acute-Onset Endophthalmitis after Cataract Surgery. Am. J. Ophthalmol. 2012, 153, 391–398.e2. [CrossRef]
7. Haapala, T.T.; Nelimarkka, L.; Saar, J.M.; Ahola, V.; Saari, K.M. Endophthalmitis Following Cataract Surgery in Southwest Finland from 1987 to 2000. Graefe’s Arch. Clin. Exp. Ophthalmol. Albrecht Graefes Arch. Klin. Exp. Ophthalmol. 2005, 243, 1010–1017. [CrossRef]
8. Ambiya, V.; Das, T.; Sharma, S.; Chhablani, J.; Dave, V.; Jalali, S.; Narayanan, R.; Joseph, J. Comparison of Clinico-Microbiological Profile and Treatment Outcome of in-House and Referred Post Cataract Surgery Endophthalmitis in a Tertiary Care Center in South India. J. Ophthalnic Inflamm. Infect. 2016, 6, 45. [CrossRef]
9. Ness, T.; Kern, W.V.; Frank, U.; Reinhard, T. Postoperative Nosocomial Endophthalmitis: Is Perioperative Antibiotic Prophylaxis Advisable? A Single Centre’s Experience. J. Hosp. Infect. 2011, 78, 138–142. [CrossRef]
10. Chiquet, C.; Aptel, F.; Combey-De Lambert, A.; Bron, A.M.; Campolmi, N.; Palombi, K.; Thuret, G.; Rouberol, F.; Cornut, P.L.; Creuzot-Garcher, C. Occurrence and Risk Factors for Retinal Detachment after Pars Plana Vitrectomy in Acute Postcataract Bacterial Endophthalmitis. Br. J. Ophthalmol. 2016, 100, 1388–1392. [CrossRef]
11. Friling, E.; Montan, P. Bacteriology and Cefuroxime Resistance in Endophthalmitis Following Cataract Surgery before and after the Introduction of Propyllic Intracameral Cefuroxime: A Retrospective Single-Centre Study. J. Hosp. Infect. 2019, 101, 88–92. [CrossRef] [PubMed]
12. Ferrer, C.; Alio, J.; Rodriguez, A.; Andreu, M.; Colom, F. Endophthalmitis Caused by Fusarium Proliferatum. J. Clin. Microbiol. 2005, 43, 5372–5375. [CrossRef] [PubMed]
13. McCannel, C.A. Meta-Analysis of Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents: Causative Organisms and Possible Prevention Strategies. Retina 2011, 31, 654–661. [CrossRef]

14. Miller, J.J.; Scott, I.U.; Flynn, H.W.; Smiddy, W.E.; Murray, T.G.; Berrocal, A.; Miller, D. Endophthalmitis Caused by Bacillus Species. Am. J. Ophthalmol. 2008, 145, 883–888. [CrossRef] [PubMed]

15. Pfugfelder, S.C.; Flynn, H.W.; Zwiecky, T.A.; Forster, R.K.; Tsiligianni, A.; Culbertson, W.W.; Mandelbaum, S. Exogenous Fungal Endophthalmitis. Ophthalmology 1988, 95, 19–30. [CrossRef]

16. Al-Torbak, A.A.; Al-Shahwan, S.; Al-Jadaan, I.; Al-Homnadi, A.; Edward, D.P. Endophthalmitis Associated with the Ahmed Glaucoma Valve Implant. Br. J. Ophthalmol. 2005, 89, 454–458. [CrossRef] [PubMed]

17. Hatami, H.; Ghaffari Jolfaiy, A.; Ebrahimi, A.; Golmohammadi, S.; Zangiabadian, M.; Nasiri, M.J. Contact Lens Associated Bacterial Keratitis: Common Organisms, Antibiotic Therapy, and Global Resistance Trends: A Systematic Review. Front. Ophthalmol. 2021, 1, 5. [CrossRef]

18. Zhang, H.; Liu, Z. Endogenous Endophthalmitis: A 10-Year Review of Culture-Positive Cases in Northern China. Ocul. Immunol. Inflamm. 2010, 18, 133–138. [CrossRef]

19. Regan, K.A.; Radhakrishnan, N.S.; Hammer, J.D.; Wilson, B.D.; Gadkowski, L.B.; Iyer, S.S.R. Endogenous Endophthalmitis: Yield of the Diagnostic Evaluation. BMC Ophthalmol. 2020, 20, 1–7. [CrossRef]

20. Gajdzis, M.; Figuła, K.; Kamińska, J.; Kaczmarek, R. Endogenous Endophthalmitis—The Clinical Significance of the Primary Source of Infection. J. Clin. Med. 2022, 11, 1183. [CrossRef]

21. Lai, C.C.; Teng, L.J.; Hsueh, P.R.; Yuan, A.; Tsai, K.C.; Tang, J.L.; Tien, H.F. Clinical and Microbiological Characteristics of Agrobacterium radiobacter Endophthalmitis. J. Hosp. Infect. 2011, 77, 193–204. [CrossRef] [PubMed]

22. Chen, C.Y.; Hansen, K.S.; Hansen, L.K. Rhizobium radiobacter as an Opportunistic Pathogen in Central Venous Catheter-Associated Bloodstream Infection: Case Report and Review. J. Hosp. Infect. 2008, 68, 203–207. [CrossRef] [PubMed]

23. Papahitou, N.I.; Rolston, K.V.I. Catheter-Related Bacteremia Caused by Agrobacterium radiobacter in a Cancer Patient: Case Report and Literature Review. Infection 2003, 31, 421–424. [CrossRef] [PubMed]

24. Hanada, S.; Iwamoto, M.; Kobayashi, N.; Ando, R.; Sasaki, S. Catheter-Related Bacteremia Caused by Agrobacterium radiobacter in a Hemodialysis Patient. Intern. Med. 2009, 48, 435–457. [CrossRef] [PubMed]

25. Miller, J.M.; Novy, C.; Hiott, M. Case of Bacterial Endophthalmitis Caused by an Agrobacterium radiobacter-like Organism. J. Clin. Microbiol. 1996, 34, 3212–3213. [CrossRef]

26. Doshi, R.R.; Leng, T.; Fung, A.E. Povidone-Iodine before Lidocaine Gel Anesthesia Achieves Surface Antisepsis. Ophthalmic Surg. Lasers Imaging 2011, 42, 346–349. [CrossRef] [PubMed]

27. Friedman, D.A.; Mason, J.O.; Emond, T.; McGwin, G. Povidone-Iodine Contact Time and Lid Speculum Use during Intravitreal Injection. Retina 2013, 33, 975–981. [CrossRef]

28. Avery, R.L.; Bakri, S.J.; Blumenkranz, M.S.; Brucker, A.J.; Cunningham, E.T.; D’amico, D.J.; Dugel, P.U.; Flynn, H.W.; Freund, K.B.; Haller, J.A.; et al. Intravitreal Injection Technique and Monitoring: Updated Guidelines of an Expert Panel. Retina 2014, 34 (Suppl. 12), S1–S18. [CrossRef]

29. Donzis, P.B.; Mondino, B.J.; Weissman, B.A.; Bruckner, D.A. Microbial Contamination of Contact Lens Care Systems. Am. J. Ophthalmol. 1987, 104, 325–333. [CrossRef]

30. Clark, B.J.; Harkins, L.S.; Munro, F.A.; Devonshire, P. Microbial Contamination of Cases Used for Storing Contact Lenses. J. Infect. 1994, 28, 293–304. [CrossRef]

31. Romano, L.; Spanu, T.; Calista, F.; Zappacosta, B.; Mignogna, S.; Sali, M.; Fiori, B.; Fadda, G. Tsukamurella Tyrosinosolvens and Rhizobium radiobacter Sepsis Presenting with Septic Pulmonary Emboli. Clin. Microbiol. Infect. 2011, 17, 1049–1052. [CrossRef]

32. Miño De Kaspar, H.; Grasbon, T.; Kampik, A. Automated Surgical Equipment Requires Routine Disinfection of Vacuum Control Manifold to Prevent Postoperative Endophthalmitis. Ophthalmology 2000, 107, 685–690. [CrossRef]

33. Rohowetz, L.J.; Yannuzzi, N.A.; Gupta, S.; Patel, N.A.; Miller, D.; Flynn, H.W. Endophthalmitis Caused by Agrobacterium radiobacter Following Intravitreal Aflibercept for Diabetic Retinopathy. Case Rep. Ophthalmol. 2020, 11, 22–27. [CrossRef] [PubMed]

34. Rohowetz, L.J.; Patel, N.A.; Quan, A.V.; Fan, K.C.; Yannuzzi, N.A.; Reyes-Capó, D.P.; Laura, D.; Ansari, Z.A.; Patel, U.; Dubovy, S.R.; et al. Agrobacterium radiobacter Endophthalmitis Associated with Baerveldt Tube Exposure. Case Rep. Ophthalmol. 2021, 12, 921–926. [CrossRef]

35. Barker, N.H.; Thompson, J.M.; Mullen, M.G.; Weekes, M.A.; Nguyen, L.N.; Haynes, C.K.M.; Miller, D. Rhizobium radiobacter: A Recently Recognized Cause of Bacterial Keratitis. Cornea 2016, 35, 679–682. [CrossRef] [PubMed]

36. Fenner, B.J.; Kumar, A.; Tan, N.Y.Q.; Ang, M. Case of Isolated Rhizobium radiobacter Contact Lens-Related Infectious Keratitis: A Plant Microbe Now Emerging as a Human Pathogen. Am. J. Ophthalmol. Case Rep. 2019, 15, 100476. [CrossRef]

37. Al-Abdullah, A.A.; Al-Falah, M.; Al-Rashaed, S.; Khandekar, R.; Arevalo, J.F. Endophthalmitis Caused by Rhizobium radiobacter After Posterior Chamber Phakic Intraocular Lens Implantation to Correct Myopia. J. Refract. Surg. 2015, 31, 561–563. [CrossRef]

38. CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.; CLSI supplement M100; Clinical Laboratory Standards Institute: Wayne, PA, USA, 2020.

39. Harbjeely, I.; Oruz, O.; Erdem, E.; Cam, B.; Demirkazik, M.; Acikalin, A.; Kibar, F.; Ilkit, M.; Yarkin, F.; Yagmur, M. Clinical Aspects and Prognosis of Polymicrobial Keratitis Caused by Different Microbial Combinations: A Retrospective Comparative Case Study. Int. Ophthalmol. 2021, 41, 3849–3860. [CrossRef]
40. Tellegen, E.; ter Riet, G.; Sloos, J.H.; van Weert, H.C.P.M. Diagnosis of Conjunctivitis in Primary Care: Comparison of Two Different Culture Procedures. *J. Clin. Pathol.* 2009, 62, 939–941. [CrossRef]

41. Chiquet, C.; Maurin, M.; Thuret, G.; Benito, Y.; Cornut, P.L.; Creuzot-Garcher, C.; Rouberol, F.; Pechinot, A.; Lina, G.; Romanet, J.P.; et al. Analysis of Diluted Vitreous Samples from Vitrectomy Is Useful in Eyes with Severe Acute Postoperative Endophthalmitis. *Ophthalmology* 2009, 116, 2437–2441. [CrossRef]

42. Namdari, H.; Hamzavi, S.; Peairs, R.R. Rhizobium (Agrobacterium) Radiobacter Identified as a Cause of Chronic Endophthalmitis Subsequent to Cataract Extraction. *J. Clin. Microbiol.* 2003, 41, 3998–4000. [CrossRef] [PubMed]

43. Lautrop, H. *Agrobacterium* spp. Isolated from Clinical Specimens. *Acta Pathol. Microbiol. Scand. Suppl.* 1967, 187, 63–64.

44. Plotkin, G.R. Agrobacterium Radiobacter Prosthetic Valve Endocarditis. *Ann. Intern. Med.* 1980, 93, 839–840. [CrossRef] [PubMed]

45. Joshi, L.; Morarji, J.; Tomkins-Netzer, O.; Lightman, S.; Taylor, S.R.J. Rhizobium Radiobacter Endophthalmitis Following Intravitreal Ranibizumab Injection. *Case Rep. Ophthalmol.* 2012, 3, 283–285. [CrossRef] [PubMed]